Skip to content
B
BiotechEdge
Start 14-Day Free Trial

Amicus Therapeutics + BioMarin

pending

$FOLD acquired by BioMarin for $4.8B

Deal Summary

Deal Value
$4.8B
Price/Share
$27
Announced
Jan 15, 2026
Expected Close
TBD

Fund Positioning

5 of 20 tracked specialist biotech funds held $FOLD — based on SEC 13F filings.

FundSharesValueEntryAt Announcement
Avoro Capital Advisors15.0M$118.4MMar 2025Yes
Perceptive Advisors6.4M$90.7MMar 2025Yes
Rock Springs Capital1.9M$27.5MMar 2025Yes
OrbiMed Advisors730K$10.4MMar 2025Yes
Redmile Group777K$6.1MMar 2025Yes
← All biotech acquisitions